Is Becton, Dickinson and Company Stock Underperforming the S&P 500?

Becton, Dickinson, and Company (BDX), headquartered in Franklin Lakes, New Jersey, is a medical technology company that develops, manufactures, and sells medical devices, medical supplies, laboratory equipment, and diagnostic products. Valued at $67.55 billion by market cap, the company offers solutions that enable medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support diabetes management.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and BDX perfectly fits that description, signifying its substantial size, stability, and dominance in its industry. The company works closely with customers and partners to help enhance outcomes, lower healthcare delivery costs, improve efficiencies, improve healthcare safety, and expand access to health.